CNTA CENTESSA PHARMACEUTICALS PLC

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Event: Jefferies Global Healthcare Conference

Date: Friday, June 9, 2023

Location: New York, NY

Fireside Chat: 10:30 AM ET

Event: Goldman Sachs 44th Annual Global Healthcare Conference

Date: Tuesday, June 13, 2023

Location: Dana Point, CA

Fireside Chat: 4:40 PM PT

Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at .

About Centessa Pharmaceuticals 

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We operate with the conviction that each one of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit , which does not form part of this release.

Contact:

Kristen K. Sheppard, Esq.

SVP of Investor Relations



EN
24/05/2023

Underlying

CNTACENTESSA PHARMACEUTICALS PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CENTESSA PHARMACEUTICALS PLC

 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Announces CEO Transition as Company Advances ...

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications  Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors BOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that its Board of Directors has appointed Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, as Chief Executive O...

December 11, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offe...

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $21.50 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $250 million, before deducting underwriting discounts and comm...

November 12, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Announces Proposed Public Offering of America...

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs offered in the public offering. The proposed offeri...

November 11, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferenc...

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: Wednesday, November 12, 2025Fireside Chat: 10:30 AM ET Event: Jefferies Global Healthcare Conference in LondonDate: Tuesday, November 18, 2025Fireside Chat: 2:0...

November 7, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Reports Financial Results for the Third Quart...

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across all three indications; Expect to initiate registrational program in Q1 2026ORX142: Phase 1 data support highly differentiate...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch